Patients with HER@-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV-PAC ( bevacizumab @ mg kg ( -@ ) days @ and @ plus paclitaxel @ mg m ( -@ ) days @ , @ and @ q@w ) or BEV-CAP ( bevacizumab @ mg kg ( -@ ) day @ plus capecitabine @ mg m ( -@ ) bid days @-@ q@w ) .